We are Indivior.

The world leader in addiction treatment with 20 years of experience and a unique, patient-focused approach.

We didn’t become the world leader in addiction treatment overnight.  Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They’re often unaware of their treatment options, have limited access to treatment, or simply don’t seek it out because they’re afraid of being stigmatized.

Since our inception, we have actively partnered with healthcare professionals, the public health community, policymakers, and payers to humanize people suffering from addiction and to treat addiction as a chronic, relapsing medical condition rather than a social disorder. We believe that people with addiction should be treated as patients, just like sufferers other chronic diseases.

The past two decades have been marked by strong growth and an expansion into more than 40 countries. While opioid dependence marketplace has seen much innovation, we at Indivior are building on our intimate understanding of the patient journey to further advance opioid dependence treatment and combat broader addiction epidemics including opiate overdose, alcohol use disorders, cocaine intoxication and schizophrenia by bringing to market novel treatment solutions worldwide.

We at Indivior are on an endeavor – one that is focused on individual patients around the world. Our name reflects this as the key words individual and endeavor harmoniously blend together. It represents and empathizes with the often difficult journey each individual patient takes to overcome the challenges of addiction – a chronic relapsing disease.

The patient continues to drive our decisions. Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit. We work with the urgency and zeal required to achieve our vision of ensuring unrestricted access to high-quality treatments for the chronic relapsing conditions and co-morbidities of addiction.

We aim to achieve this vision by living our patient-focused business model and adhering to the three pillars of our strategic plan:

Invest in Pioneering Change

We will invest in innovating our market-leading products, discovering and developing new medications, and expanding patient treatment access infrastructure. We will accomplish this by:

Strengthening Leadership in Opioid Addiction Treatment: Further enhance delivery, decrease dosing, and increase adherence and retention of our market-leading physician and patient-preferred buprenorphine therapies.

Delivering New Treatments to Address Patients’ Unmet Needs: Leverage our expertise in neuroscience to discover and develop new treatments for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions such as schizophrenia.

Expanding Patient Access to Treatment: Engage with government, key opinion leaders, physicians, healthcare providers, payers, and patient advocacy groups to expand access to treatment and improve patient outcomes.

Advance Scientific and Societal Understanding of Addiction

We will help to improve patients’ lives by raising awareness and scientific understanding of the disease and facilitating access to information and resources. We will do this by:

Catalyzing Change in Perceptions: Raise awareness and educate about addiction as a chronic, relapsing disease to help remove the stigma of addiction and encourage patients to seek treatment.

Advancing Scientific Understanding: Collaborate with the healthcare and scientific communities to increase our mutual understanding of the unmet needs of patients and the most effective ways to deliver our best available treatments.

Encouraging Patients to Act: Help patients take the first step on their journey by ensuring widely available, easy-to- access information and resource on treatments, healthcare providers, and disease management.

Activate global partnerships to make resources for patients more accessible worldwide.

We will initiate global and community-based partnerships to change the disease landscape by:

Ensuring Treatment Integrity: Minimize diversion, misuse and abuse of addiction medications through close collaboration with regulators, physicians and pharmacists, and activate risk management programs to ensure patient safety.

Innovating in Crisis Prevention: Connect front-line providers in communities with much needed, consumer-friendly overdose treatments that can help bridge patients from crisis to life-sustaining treatment.

Advocating for Multi-Sector Collaboration: Engage government, payors, healthcare professionals, and communities to more proactively address the disease of addiction and find more effective ways to prevent addiction and encourage treatment.